Damaged mitochondria undergo mitophagy, a specialized form of autophagy that is initiated by the protein kinase PINK1 and the ubiquitin E3 ligase Parkin. Ubiquitin-specific protease USP30 antagonizes Parkin-mediated ubiquitination events on mitochondria and is a key negative regulator of mitophagy. Parkin and USP30 both show a preference for assembly or disassembly, respectively, of Lys6-linked polyubiquitin, a chain type that has not been well studied. Here we report crystal structures of human USP30 bound to monoubiquitin and Lys6-linked diubiquitin, which explain how USP30 achieves Lys6-linkage preference through unique ubiquitin binding interfaces. We assess the interplay between USP30, PINK1 and Parkin and show that distally phosphorylated ubiquitin chains impair USP30 activity. Lys6-linkage-specific affimers identify numerous mitochondrial substrates for this modification, and we show that USP30 regulates Lys6-polyubiquitinated TOM20. Our work provides insights into the architecture, activity and regulation of USP30, which will aid drug design against this and related enzymes.
a r t i c l e s Protein ubiquitination regulates virtually all aspects of cellular biology, in particular protein homeostasis [1] [2] [3] [4] . In addition to protein degradation via the proteasome system, ubiquitin also regulates lysosomal degradation of protein complexes and organelles through autophagy. The last few years have seen great leaps in our understanding of a specialized form of autophagy termed mitophagy, which targets damaged parts of mitochondria for autophagic clearance [4] [5] [6] [7] .
Mitophagy ensues upon mitochondrial membrane depolarization, which leads to stabilization of the ubiquitin kinase PINK1 on the cytosolic face of the mitochondrial outer membrane (MOM) 8 . Here, PINK1 phosphorylates ubiquitin attached to mitochondrial proteins [9] [10] [11] [12] [13] , and this recruits and activates the ubiquitin E3 ligase Parkin [14] [15] [16] [17] . PINK1 phosphorylates and thereby fully activates recruited Parkin 18 , which in turn hyperubiquitinates mitochondrial proteins on hundreds of sites 19 forming various types of ubiquitin linkages 12, 20, 21 . Mitochondrial (phospho)ubiquitination recruits mitophagy receptors as well as the autophagic machinery, and mitophagy proceeds 5, 22, 23 . This process occurs in response to endogenous mitochondrial damage 24 and can also be induced by chemical depolarization 5, 6 . Notably, loss-of-function mutations in Parkin and PINK1 lead to early-onset autosomal recessive juvenile Parkinsonism (AR-JP), a neurodegenerative disorder arising from loss of dopaminergic neurons in the substantia nigra 5, 25 . To date there are no treatments to stall AR-JP or other forms of Parkinson's disease.
Deubiquitinases (DUBs) reverse ubiquitin modifications and are thus important regulators of the ubiquitin system 26, 27 . Parkin activity is reportedly counteracted by various DUBs including USP8 (ref. 20) , USP15 (ref. 28 ), USP30 (refs. [29] [30] [31] and USP35 (ref. 32 ). Among those, USP30 is the only active DUB known to be constitutively anchored in the MOM 33, 34 . Importantly, Parkin and USP30 assemble 12, 20 or disassemble 13, 31 , respectively, a similar set of ubiquitin linkages, sharing a preference for Lys6-linked chains. This ubiquitin chain type has important yet obscure roles in mitophagy 21 and the DNA damage response 4, 35 , and it is assembled by bacterial effector E3 ligases 36, 37 , but direct substrates are unknown. The reported Lys6linkage preference of USP30 is unusual, as USP domain DUBs do not, with few exceptions, distinguish among ubiquitin chain types 26, 38, 39 . Functionally, USP30 is a regulator of mitochondrial morphology 40 and mitophagy, and its loss or decreased levels lead to increased mitochondrial turnover [29] [30] [31] 41 . Inhibition of USP30 has consequently been proposed as a therapeutic means of re-establishing the balance between mitochondrial ubiquitination and deubiquitination in neurodegenerative disorders including Parkinson's disease 29 .
To understand USP30 mechanistically and functionally, we performed structural and biophysical studies to reveal the molecular basis for USP30's Lys6 preference. We further reconstituted USP30 regulatory mechanisms in vitro and found that even incomplete PINK1 kinase-mediated ubiquitin chain phosphorylation affects USP30 activity. Finally, we exploited Lys6-linkage-specific affimer reagents 42 to identify mitochondrial proteins that are modified with this linkage type during mitophagy and found that USP30 regulates Lys6 polyubiquitination of TOM20.
RESULTS

Optimizing USP30 for crystallography
Human USP30 comprises 517 amino acids (aa) and includes a mitochondrial intermembrane part (residues 1-35), a single transmembrane helix (residues 36-56) and a cytoplasmic catalytic domain a r t i c l e s (residues 57-517) that encodes the observed Lys6 preference 13, 31 . A USP30 version with minimal boundaries (residues 64-502, USP30 c2 ) ( Fig. 1a) cleaved Lys6-linked diubiquitin (Lys6-diUb) preferentially over Lys11-and Lys48-linked chains ( Fig. 1b and Supplementary  Fig. 1a) , an effect that was more pronounced when tetraubiquitin substrates were used ( Fig. 1c and Supplementary Fig. 1b ; all constructs used in this study are listed in Supplementary Table 1 ). As this construct resisted crystallization, we dissected the catalytic domain on the basis of the previously reported USP box annotation 43 (Fig. 1a,d,  Supplementary Fig. 1c,d and Supplementary Note 1) , revealing multiple insertions in the catalytic domain. USP30 insertions are poorly conserved ( Supplementary Fig. 1e and Supplementary Note 1) and are seemingly flexible, as indicated by high deuterium uptake in hydrogen-deuterium exchange mass spectrometry (HDX-MS) measurements ( Fig. 1d and Supplementary Fig. 1e ). Removing a flexible, proline-rich 74-aa insertion between boxes 4 and 5 resulted in Figure 1 Linkage preference, construct optimization and structures of USP30. (a) Constructs of human USP30 used in this study. The mitochondrial intermembrane part (M), transmembrane helix (α), catalytic residues and annotation of boxes of the cytosolic USP domain 43 are shown (see also Supplementary Table 1 ). (b) Time-course analysis of indicated diubiquitin cleavage with USP30 catalytic domain (construct 2, USP30 c2 ) resolved by SDS-PAGE and visualized by silver staining. (c) Tetraubiquitin cleavage analysis as in b. Gels in b and c are representative of triplicate experiments (see also Supplementary Fig. 1a,b ). (d) Deuterium incorporation obtained from HDX-MS for USP30 c2 , indicating flexible parts (red) in the insertions between USP boxes 2 and 3, and 4 and 5 (see also Supplementary Fig. 1c -e). (e,f) Specificity analysis as in b for indicated USP30 constructs lacking insertions. Gels are representative of duplicate experiments. (g-i) Cartoon representation of covalent USP30 c13~U b-PA (g), USP30 c8~U b-PA (h) and inactive USP30 c13 C77A noncovalently bound to Lys6-diUb (USP30 c13i -Lys6-diUb, i). Ubiquitin molecules are shown with transparent surfaces (for further details, see Supplementary Fig. 3 and Table 1 ; uncropped gel images are shown in Supplementary Data Set 1). a r t i c l e s aggregation-prone protein with low solubility ( Supplementary Table 1 ). Modeling with known USP domain structures suggested that insert deletion might expose hydrophobic residues Phe348, Met350 and Ile353 (Supplementary Fig. 2a ). Mutation of those to hydrophilic residues eventually generated USP30 c8 (Fig. 1a) , which showed improved expression levels, activity and solubility ( Supplementary Table 1 and Supplementary Fig. 2b-f ). USP30 c8 crystallized in complex with the ubiquitin-based suicide probe ubiquitin-propargylamine 44 (Ub-PA), but low resolution (3.6 Å) and twinning initially prevented structure determination.
Deletion of an additional, flexible 38-aa insertion between boxes 2 and 3 in USP30 c13 further increased protein stability (Fig. 1a,d and Supplementary Fig. 2c ), yet did not affect substrate preference ( Fig. 1e,f) . USP30 c13 readily crystallized in complex with Ub-PA, resulting in a 2.3-Å USP30~Ub-PA structure that was used to phase the twinned USP30 c8~U b-PA data set ( Fig. 1g,h, Supplementary  Fig. 3a-c and Table 1 ). Moreover, mutation of catalytic Cys77 to alanine resulted in inactive USP30 (USP30 c13i ) ( Supplementary  Table 1 ) that formed a complex with Lys6-diUb on analytical gel filtration ( Supplementary Fig. 3d ). A crystal structure of USP30 c13i in complex with Lys6-diUb (USP30 c13i -Lys6-diUb) was determined at 2.8-Å resolution ( Fig. 1i, Supplementary Fig. 3e ,f and Table 1 ). Additional HDX-MS experiments confirmed that the insertion between boxes 2 and 3 is not involved in distal ubiquitin binding ( Supplementary  Fig. 4) . Collectively, the structures reveal several unique features of USP30 and explain how USP30 achieves Lys6 preference.
Unusual features of USP30
Binding modes for the distal ubiquitin were identical in mono-and diubiquitin USP30 complexes ( Fig. 1g-i) . The overall orientation of ubiquitin was similar to previously determined USP~ubiquitin complexes such as USP7 (ref. 45) ( Fig. 2a ) or USP21 (ref. 46 ) but differed in how the ubiquitin C terminus is guided into the active site. Most USP DUBs form near-identical and conserved backbone hydrogen bonds to all ubiquitin tail residues ( Fig. 2a) . USP30 lacks several of these interactions and has three fewer hydrogen bonds than other USPs, such as USP7 ( Fig. 2a and Supplementary Fig. 5a ), which suggests that binding of the distal ubiquitin has been selectively weakened. This explains complications with estimating USP30 K M values for monoubiquitin substrates 31, 38 or K d values for the interaction between inactive USP30 and fluorescent ubiquitin ( Fig. 2b and Supplementary Fig. 5b,c) ; similar substrates bind other (inactive) USPs with nanomolar to low micromolar affinities 46, 47 (Supplementary Fig. 5d ).
USP30 is one of three USPs (with USP16 and USP45) that feature a serine as part of their catalytic triad 43 (in USP30, Cys77, His452 and Ser477). In the USP30 c13~U b-PA structure, the Ser477 side chain forms a hydrogen bond with catalytic His452, implying a threemembered catalytic charge-relay system ( Fig. 2c) . As expected, cysteine and histidine mutations abrogated USP30 activity, while serine mutations to alanine, asparagine or aspartic acid, the latter two of which are usually found in USP DUBs 43 , reduced activity in both mono-and diubiquitin-based substrate cleavage assays (Fig. 2d,e and Supplementary  Fig. 5e,f) . Taken together, these data demonstrate the functional importance of the unusual serine in the USP30 catalytic triad.
Explaining Lys6-linkage preference in USP30
DUBs achieve ubiquitin-chain-linkage preference by providing a defined binding site that positions the proximal ubiquitin with respect to the active site 26 . Indeed, fluorescently labeled Lys6-diUb bound inactive USP30 with a K d of ~4 µM, whereas other chain types showed poor or no binding in the concentration range assessed (up to 60 µM diubiquitin) ( Fig. 3a and Supplementary Fig. 6a,b) . Unlabeled Lys6-diUb bound with similar K d in isothermal titration calorimetry experiments ( Fig. 3b and Supplementary Fig. 6c ) and increased thermal stability of USP30, which was not observed for monoubiquitin or other diubiquitin linkages ( Fig. 3c ). This indicates that USP30 achieves its linkage preference by specifically interacting with Lys6-polyubiquitin.
The USP30 diubiquitin complex structure (Figs. 1i and 3d) explains this preferential binding and reveals how the proximal ubiquitin interacts with USP30 in three areas ( Fig. 3d-f ). The first and most prominent region contacted by the ubiquitin Phe4 patch localizes to a hydrophobic surface on the USP30 palm subdomain that comprises conserved residues His445 and catalytic His452, as well as Trp475, which is not present in any other USP DUB 43 . Ubiquitin Phe4 and Thr12 thereby sit atop the catalytic triad and shield it from solvent.
The second region of the interface is mediated by the ubiquitin β1 and β2 strands and the Leu8 loop ( Fig. 3d,f and Supplementary Fig. 6d ), which contact USP30 loops from thumb (residues 71-74) and palm (β12-β13 hairpin) subdomains, forming five hydrogen bonds.
Third, several interactions surround the ubiquitin Lys6 side chain that reaches into the active site ( Fig. 3d,f) . The ubiquitin isopeptide bond is fully engulfed by USP30, and residues from the thumb subdomain (Glu159 and Asn75) reach over the ubiquitin binding channel to contact the palm subdomain ( Fig. 3d,e and a r t i c l e s Supplementary Fig. 6e,f) . This shields the isopeptide and catalytic center from solvent but also stretches out the diubiquitin, which adopts a conformation distinct from that of its compact solution structure 37 (Supplementary Fig. 7) . The distal ubiquitin interaction is considerably stronger than the proximal ubiquitin binding site (1,652 Å 2 versus 535 Å 2 buried surface area; 49 versus 10 polar interactions; solvation-free energy −6.4 versus −2.0 kcal/mol), but the proximal ubiquitin binding site provides the observed linkage preference. Notably, catalytic Ser477 contributes to the proximal interface, and specificity characterizations revealed that USP30 S477D has lost Lys6-linkage preference ( Fig. 3g and Supplementary Fig. 6g,h) . Similarly, USP30 mutations of His445 or Trp475 that disrupt the Phe4 binding interface of the proximal ubiquitin were less active and, notably, less specific than wild-type USP30 ( Fig. 3h and Supplementary Fig. 8 ). Hence, mutations in the proximal ubiquitin binding site reduce the observed linkage preference of USP30.
Together, these results offer a straightforward model for how USP30 achieves its Lys6-preference, namely by balancing distal and proximal ubiquitin interactions such that Lys6-linked chains are bound preferentially (Fig. 4a) . The presence of a proximal ubiquitin binding site distinguishes USP30 from other USP enzymes, which commonly comprise only a high-affinity distal ubiquitin binding site and consequently often lack a pronounced linkage preference 26, 38, 39 (Fig. 4b) . The only other case where USP linkage specificity has been reported and molecularly understood is CYLD, which prefers Lys63-and Met1-linked chains [48] [49] [50] . CYLD uses a mechanism that is conceptually similar to USP30 ( Fig. 4c ) but differs at the molecular level. Structures of CYLD with Lys63-and Met1-linked diubiquitin revealed how a divergent domain architecture gives rise to distinct and CYLD-specific ubiquitin binding modes 50 . Superposition of USP30 and CYLD complexes shows how the proximal binding sites diverge to enable either enzyme to target distinct linkage types ( Fig. 4d-f and Supplementary Fig. 9 ). Whereas USP30 uses an interface embedded into its USP domain, CYLD utilizes an inserted β-sheet protruding out of its catalytic domain to position the proximal ubiquitin ( Fig. 4a,c) . Further specificity and structural studies of USP enzymes are likely to reveal additional features of binding sites for a proximal ubiquitin or substrate protein.
Ubiquitination of USP30 by Parkin
USP30 antagonizes mitophagy 29, 31 , and Parkin and PINK1, the key signaling molecules in mitophagy, may be able to regulate USP30 (refs. 13, 29, 31) . Parkin ubiquitinates USP30 in cells, which may lead to its degradation 29 . In vitro reconstitution of USP30 ubiquitination by phosphorylated Parkin (Fig. 5a a r t i c l e s Fig. 10a ) revealed monoubiquitination on Lys235 and Lys289 at the tip of the fingers subdomain and on Lys310 in the distal ubiquitin binding site ( Fig. 5b and Supplementary Table 2 ), matching sites previously found in cells 29, 31 . Notably, although Parkin assembled ubiquitin chains in these reactions, USP30 appeared to be predominantly monoubiquitinated ( Fig. 5a and Supplementary Fig. 10a ). (1), ubiquitin β1-β2 loop coordination by the USP30 thumb and palm domains (2) and ubiquitin-Lys6 interaction within the catalytic center near the oxyanion hole (Cys77 and Asn72) (3). (g) Diubiquitin cleavage assay with indicated substrates and Ser477 mutants, titrated to similar activity levels ( Supplementary Fig. 6g ,h).
(h) Diubiquitin specificity assay (as in Fig. 1b ) with USP30 mutants in the proximal binding site (W475K or H445E) that abrogate specificity. Gel-based assays in g and h were performed in triplicate and duplicate, respectively (uncropped gel images are shown in Supplementary Data Set 1). WT, wild type.
a r t i c l e s Monoubiquitinated forms of USP30 have been reported in cells and are relatively stable, compared to other Parkin substrates 30 . To test whether monoubiquitination affects USP30 activity, we had to overcome the challenge posed by USP30's in vitro auto-deubiquitination ( Fig. 5a ). We modified USP30 with a ubiquitin mutant, ubiquitin F4R, that was efficiently attached to USP30 by Parkin but prevented autodeubiquitination, as USP30 was no longer able to bind it for structural reasons ( Fig. 5c and Supplementary Fig. 10b,c) . We were surprised to find that there was no distinguishable difference in activity between monoubiquitinated USP30 and unmodified USP30 as assessed by a ubiquitin-KG-TAMRA substrate cleavage assay ( Fig. 5c) . Thus, while Parkin-mediated monoubiquitination of USP30 can be reconstituted in vitro, its impact on USP30 function is less clear: monoubiquitinated USP30 is active and unlikely to be directly targeted for proteasomal degradation.
Indirect regulation of USP30 by PINK1
PINK1 generates Ser65-phosphorylated ubiquitin (phosphoubiquitin), and phosphorylated Lys6-diUb is a poor USP30 substrate 13 . However, Parkin is unable to assemble phosphoubiquitin into chains 13 , and only 20% of mitochondrial ubiquitin is phosphorylated upon chemical depolarization 21 . Although we and others have shown that polyubiquitin can be phosphorylated by PINK1 (refs. 13,51), we wondered whether PINK1 targets distinct chain types with different kinetics.
To this end, we characterized Lys6-, Lys11-, Lys48-and Lys63-linked di-and tetraubiquitin phosphorylation in an intact protein mass spectrometry-based assay ( Fig. 6a-c) . Time-course analysis revealed similar rates for the first phosphorylation event in all chain types, but we noticed that phosphorylation of Lys6-diUb showed biphasic behavior, with the second phosphorylation event occurring slower than the first (Fig. 6a) . Analysis of asymmetric Lys6-diubiquitin phosphorylation revealed that this chain type is first phosphorylated on the distal ubiquitin ( Supplementary Fig. 11a ). This is consistent with the conformation of Lys6-linked chains in solution 37 , in which Ser65 is fully exposed only on the distal ubiquitin, which probably explains the delayed phosphorylation kinetics on the proximal ubiquitin molecules in Lys6-diubiquitin or Lys6-tetraubiquitin ( Fig. 6a-c) . This behavior is in contrast to Lys63-linked chains, which are phosphorylated rapidly on each ubiquitin molecule (Fig. 6b,c) a r t i c l e s charged USP30 residues ( Fig. 6d and Supplementary Fig. 11b ).
Structural characterization revealed that Ser65-phosphorylated ubiquitin exists in a slowly exchanging equilibrium between a 'common' ubiquitin conformation and a conformation in which the ubiquitin C terminus is retracted 13, 52 . The latter conformation is structurally incompatible with productive binding in the distal ubiquitin binding site of USP DUBs 13 . USP30 hydrolyzed phosphorylated ubiquitin-KG-TAMRA with ~8-fold lower efficiency than it hydrolyzed unphosphorylated ubiquitin-KG-TAMRA ( Fig. 6e and Supplementary  Fig. 11c-e ), and phosphorylation of monoubiquitinated inactive USP30 consistently impaired deubiquitination by active USP30 (Fig. 6f,g and Supplementary Fig. 12a ). This suggests that substrates where phosphoubiquitin would engage the distal ubiquitin binding site are more resistant to deubiquitination by USP30. This extends to Lys6-, Lys11-, Lys48-and Lys63-linked diubiquitin, all of which are worse substrates for USP30 when phosphorylated 13 (Fig. 6h) as they would engage the distal ubiquitin binding site.
To investigate in more detail whether both distal and proximal ubiquitin binding sites of USP30 are susceptible to regulation through phosphoubiquitin, we assembled Lys6-diUbs with phosphorylation of Ser65 on the distal, proximal or both ubiquitin moieties (Supplementary Fig. 12b ). Gel-based kinetics showed that phosphorylation of the distal but not the proximal ubiquitin resulted in diminished USP30 activity (Fig. 6i,j) . Notably, however, a singly phosphorylated Lys6-tetraubiquitin species with one phosphoubiquitin at the distal tip was protected from USP30-mediated hydrolysis to a similar degree as an almost fully phosphorylated tetraubiquitin (Fig. 6k) . Hence, despite containing unphosphorylated Lys6 linkages, a singly phosphorylated Lys6-linked chain is a poor USP30 substrate.
This observation can be explained structurally. Like other USP enzymes 37 , USP30 is a compulsory exo-DUB 26 toward Lys6 linkages; i.e., it hydrolyzes this chain type exclusively from the distal end (Supplementary Fig 1b) . Lys6 of the distal ubiquitin is shielded by the fingers subdomain in the distal ubiquitin binding site ( Supplementary  Fig. 10b ), disallowing chain extension on Lys6; as a result, only the unmodified tip of Lys6-linked chains can interact with a USP, explaining exo-DUB activity. Phosphorylation of this distal ubiquitin by PINK1 thus protects the entire Lys6-linked chain from USP30mediated hydrolysis.
Role of USP30 in regulating mitochondrial ubiquitination
We next considered how our biochemical and structural insights into USP30 could be linked with its physiological context. USP30 is anchored on the surface of mitochondria, and only ten residues bridge the transmembrane helix and the start of the catalytic domain. This probably imposes restrictions for substrate accessibility. Indeed, USP30 regulates numerous ubiquitination sites on MOM proteins 29, 30, 32, 40 , which indicates that USP30, in addition to targeting polyubiquitin chains, can hydrolyze the isopeptide bond between substrate and the first ubiquitin. The accessible active site geometry of the USP domain, while designed to discriminate ubiquitin linkages, would allow this substrate promiscuity.
The emergence of Lys6-polyubiquitin on mitochondria has been linked to Parkin activation upon mitochondrial damage 12, 20, 21, 31 . Mitochondrial Lys6-polyubiquitin increases fivefold when USP30 is deleted, while other chain types remain unchanged 31 . This suggests that the preferred hydrolysis of Lys6 linkages by USP30 contributes to shaping the polyubiquitin pool on mitochondria. However, it is not known which MOM proteins are modified with Lys6 linkages, and the abundance of Lys6 linkages in cells is very low (between 0.5 and 2% of all linkages) 53, 54 . Linkage-specific antibodies can show that proteins are modified with a particular chain type [55] [56] [57] but are not available for the Lys6 linkage. Recently developed chain-linkage-specific affimers 42 allowed us to investigate Lys6-ubiquitin chains in a mitochondrial context. Enrichment of Lys6-ubiquitinated proteins with the affimer using HeLa Flp-In T-REx cells that inducibly express wildtype Parkin 12 facilitated the detection of ubiquitinated forms of MOM proteins TOM20, VDAC1, MFN2, MIRO1 and CISD1 ( Fig. 7a and Supplementary Fig. 13a ), which are known substrates of Parkin 19 , in a Parkin-and depolarization-dependent manner. Consistent with the requirement for a Lys6 linkage, the monoubiquitinated forms of these proteins were not enriched (Fig. 7a) . Notably, Lys6-polyubiquitin signals of TOM20, but not of other MOM proteins tested, were increased upon knockdown of USP30 (Fig. 7b,c and Supplementary  Fig. 13b,c) . Moreover, expression of USP30 or catalytically inactive USP30 C77A led to a decrease or increase of TOM20 Lys6-ubiquitination, respectively (Fig. 7d,e ). In addition, overexpression of active USP30 resulted in reduced levels of Lys6-ubiquitinated forms of other proteins as well ( Fig. 7d and Supplementary Fig. 13d,e ). Together, affimer-based detection confirms that Lys6-linked chains become abundant on mitochondrial proteins 31, 42 and reveal direct substrates for this unstudied ubiquitin modification. Lys6 linkages on TOM20 correlate with levels of USP30 and may represent a direct readout of USP30 cellular activity.
DISCUSSION
We here reveal how USP30, the only human DUB directly inserted in the outer mitochondrial membrane, achieves a preference for the unstudied Lys6-ubiquitin chain type. We further show how USP30 is regulated by PINK1 and Parkin that initiate mitophagy and how Table 2 ) mapped on a cartoon representation of USP30. These match annotated sites in cell lines 29, 31 and cluster at the tip of the fingers subdomain. (c) Active USP30 c13 was modified by Parkin with ubiquitin F4R, which prevents auto-deubiquitination. Left, separation of free and modified forms by ion-exchange chromatography; right, USP30 activities, determined in ubiquitin-KG-TAMRA assays. Data are mean ± s.e.m. from triplicate measurements (see also Supplementary Fig. 10 ; uncropped gel images are shown in Supplementary Data Set 1). WT, wild type. 13 on the proximal and distal ubiquitin in the USP30-Lys6-diUb complex places the phosphate groups at USP30-ubiquitin interfaces ( Supplementary Fig. 11b ). a r t i c l e s it regulates the deubiquitination of mitochondrial proteins, including TOM20, during mitophagy. The identification of substrates for Lys6-polyubiquitin modification using new affinity tools for this linkage type supports important roles of this chain type, in addition or in conjunction with phosphoubiquitin, as a mitophagy-inducing signal 21 . Moreover, it has been shown previously that cells expressing a non-ubiquitinatable form of TOM20 do not efficiently undergo mitophagy 29 , on the basis of findings that USP30 directly regulates TOM20 ubiquitination (i.e., it cleaves the bond between TOM20 and the 'first' ubiquitin). We extend this here by showing that TOM20 a r t i c l e s is modified with Lys6-linked chains in a Parkin-dependent manner. USP30 interacts directly with TOM20 (ref. 30 ) and stabilizes it during mitophagy induction 29, 30 , while USP30 knockdown increases TOM20 Lys6-ubiquitination. Hence, it is tempting to speculate that USP30 regulates mitophagy at least in part by regulating TOM20 ubiquitination (Fig. 7f) . It will now be important to understand the special role of TOM20 and how its Lys6-ubiquitination mechanistically regulates mitophagy, and which other proteins behave similarly to TOM20 during mitophagy. There could be many reasons for the observation that Lys6 modifications of other proteins seem not to be regulated by USP30 knockdown. For example, USP30 may require physical proximity to its substrates 30 or appropriate chain architectures to be efficient. Also, PINK1 activity may protect some of the observed ubiquitination events from USP30 cleavage. It seems counterintuitive that USP30 can antagonize mitophagy, as it is ubiquitinated by Parkin 29 and potentially degraded, and also seemingly unable to efficiently process PINK1-induced phosphoubiquitin signals (Fig. 6) . Our results and previous data 29, 30 seem consistent with a model in which USP30 may not act in a negative feedback loop to stop mitophagy after initiation but constitutively counteracts initiation of mitophagy (and possibly other mitochondrial ubiquitination events). In such a model, USP30 may keep mitochondrial ubiquitination below a threshold that is required to efficiently trigger mitophagy. Activation of PINK1 and Parkin would disturb this equilibrium by depositing large amounts of (poly)ubiquitin and phosphoubiquitin to overcome USP30 activity. This would explain data obtained under depolarization conditions, where USP30 knockdown or loss increases mitophagy [29] [30] [31] . In a physiological scenario, mitochondria undergo fission and fusion processes and, upon localized damage, are able to isolate and degrade affected parts of the mitochondrial network. USP30 here may be able to respond locally to the PINK1 or Parkin status, and it is tempting to speculate that this may allow USP30 to contribute to defining the spatial extent of the mitophagized area (Supplementary Fig. 14) , for example by regulating concomitant fission or fusion events 40 . These cell-biological questions are not easy to address and will require detailed high-resolution assessment of mitophagy mechanisms.
Taken together, our data contribute to explaining how USP30 can act as a brake on mitophagy. As previously noted, this makes USP30 an attractive drug target, particularly in conditions in which mitophagy initiation is compromised, as in patients with Parkin mutations. An inhibitor of USP30 may here lower the threshold for mitophagy induction, which has been shown to proceed in cells expressing very low Parkin levels that nonetheless rely on mitochondrial ubiquitin 22 . The reported structural differences between USP30 and other USP-family DUBs reported here improve the prospects of finding USP30-specific inhibitors, which may benefit patients with earlyonset Parkinson's disease but may also be useful in other contexts of mitochondrial dysfunction.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METHODS
Cloning and constructs. cDNA of human USP30 (UniProt Q70CQ3) was obtained from GeneArt Gene Synthesis with codon optimization for bacterial expression. All constructs ( Supplementary Table 1 ) were cloned into pOPIN vectors 58 using the In-Fusion HD Cloning Kit (Takara Clontech). Site-directed mutagenesis was carried out using the QuikChange method or with overlap extension PCR 59 .
USP30 constructs were cloned with an N-terminal hexahistidine (His 6 ) tag, a 3C protease cleavage site, a glutathione-S-transferase (GST) tag and another 3C protease cleavage site followed by the protein sequence. The chosen purification strategy exploits the ability of untagged human USP30 to weakly bind to Ni-NTA resin facilitating separation from free GST.
Point mutations were introduced into construct 2 (boundaries 64-502, no deletions or additional mutations) unless noted otherwise.
Protein expression and purification. E. coli Rosetta2 pLacI cells (Novagen) were chemically transformed with expression vector and subsequently grown in 2xTY medium supplemented with appropriate antibiotics to an optical density (OD 600 ) of 0.8-1.0 at 30 °C. After cooling down to 18 °C for ~1 h, expression was induced by addition of 0.5 mM isopropyl-β-d-1-thiogalactopyranoside (IPTG) and cells were kept shaking for 18 h at 18 °C. After harvest by centrifugation, cell pellets were flash frozen in liquid nitrogen and stored at −80 °C.
Cells were resuspended in lysis buffer (50 mM sodium phosphate, pH 8.0, 300 mM sodium chloride, 5 mM β-mercaptoethanol, 20 mM imidazole) supplemented with 2 mg/mL lysozyme, 0.2 mg/mL DNaseI and one EDTAfree Complete Protease Inhibitor Cocktail tablet (Roche). The suspension was then incubated on ice for 20 min, sonicated for 5 min (10 s on/10 s off, 62 W), cleared by centrifugation at 22,500 × g for 30 min at 4 °C and filtered through a 0.45-µm filter.
All following purification steps were carried out on an Äkta Explorer system (GE Healthcare) at 4 °C. For affinity chromatography, lysate was loaded onto a pre-equilibrated 5-mL HisTrap Fast Flow column (GE Healthcare), washed with 10 column volumes (CV) of lysis buffer, washed with 12 CV lysis buffer supplemented with additional 20 mM imidazole and then eluted with a linear gradient over 5 CV into elution buffer (50 mM sodium phosphate, pH 8.0, 300 mM sodium chloride, 5 mM β-mercaptoethanol, 500 mM imidazole). Protein-containing fractions were pooled, supplemented with His 6 -tagged 3C protease and dialyzed against lysis buffer at 4 °C for 4-24 h. The next round of affinity purification enriches untagged human USP30 on Ni-NTA resin while free GST is separated out through the flow through. The dialyzed solution was diluted twofold with lysis buffer and passed through a 5-mL HisTrap FastFlow column. After washing with lysis buffer for 10 CV, USP30 was eluted as described above. Protein-containing fractions were pooled and dialyzed at 4 °C into buffer A (25 mM Tris, pH 8.5, 50 mM NaCl, 5 mM DTT) for 4-24 h. Samples were then subjected to anion-exchange chromatography on a 6-mL Resource Q column (GE Healthcare) with linear elution into buffer B (25 mM Tris, pH 8.5, 500 mM NaCl, 5 mM DTT) and final size-exclusion chromatography (HiLoad 16/600 Superdex 75 pg, GE Healthcare) in buffer C (20 mM Tris, pH 8.0, 100 mM NaCl, 5 mM DTT). Purity of peak fractions was assessed by SDS-PAGE before pooling, concentrating at 4 °C / 3,200 × g in spin concentrators (10 kDa MWCO, Viva spin) and flash freezing in liquid nitrogen. All protein concentrations were determined by absorption at 280 nm unless noted otherwise. USP21 (ref. 46 ), GST-tagged PhPINK1 (ref. 14) , full-length HsParkin 14 , ubiquitin and ubiquitin chains 60 were expressed, purified and assembled as described previously.
Assembly of ubiquitin-propargylamine suicide probe. Ub(1-75)-MesNa (Ub(1-75) conjugated to 2-mercaptoethanesulfonate as a sodium salt) was prepared as described previously 61 . 0.7 g propargylamine hydrochloride (Aldrich, P5091) was dissolved in 7 mL buffer D (20 mM HEPES, 50 mM sodium acetate, pH 6.5, 75 mM sodium chloride), supplemented with 490 µL 4 M sodium hydroxide, and added to 6 mL 600 µM Ub(1-75)-MesNa in buffer D. The final pH of the reaction mixture was between 8.0 and 8.5. Following incubation at room temperature for 3 h, completion of the reaction was observed by intact protein mass spectrometry (expected mass, 8,544.8 Da; mass found, 8,544.1 Da). The reaction mixture was then concentrated to 2.5 mL in a spin concentrator (3 kDa MWCO, Amicon Ultra) for size-exclusion chromatography (HiLoad 16/600 Superdex 75 pg, GE Healthcare) in buffer D to yield ubiquitin(1-75)-propargylamine suicide probe (Ub-PA) 44 .
Modification of USP30 with Ub-PA suicide probe. Following the second affinity purification step, USP30 was mixed with 1.3 equivalents of Ub-PA, dialyzed into buffer B and further purified by anion-exchange and size-exclusion chromatography as described above. Crystals were soaked in mother liquor supplemented with 25-30% (v/v) glycerol before vitrification in liquid nitrogen.
Crystallization
Data collection, structure determination and refinement. Diffraction data were collected at the Diamond Light Source, Harwell, UK, at 100 K at beamlines I04-1 (wavelength: 0.9282 Å), I02 (wavelength: 0.9795 Å) and I24 (wavelength: 0.9686 Å) for the 3.6 Å, 2.3 Å and 2.8 Å data sets, respectively. Diffraction images were indexed and integrated using XDS 62 or DIALS 63 , and scaled using AIMLESS 64 (Wilson B-factors: 136.3 Å 2 , 31.8 Å 2 and 49.3 Å 2 ). The USP30 c13~U b-PA structure was determined from the 2.3-Å data set by molecular replacement using PHASER 65 with a chainsaw 66 model derived from the structure of USP2 covalently bound to ubiquitin (PDB 2HD5) 47 . Phases for the USP30 c13i + Lys6-diUb complex were obtained by molecular replacement using the coordinates of the 2.3-Å USP30 c13~U b-PA data set and another copy of C-terminally truncated ubiquitin (residues 1-72, PDB 1UBQ) 67 . The twinned 3.6-Å data set of USP30 c8~U b-PA was solved in space group P6 5 with two molecules per asymmetric unit by molecular replacement using the 2.3-Å structure of USP30 c13~U b-PA as search model (twin law: h, k, l = k, h, −l; twin fractions: 0.52 / 0.48). The final refinement of the 3.6-Å structure was carried out with external restraints using ProSmart 68 against the geometry of the 2.3-Å structure. The resulting 3.6-Å map allows for clear tracing of the polypeptide chain and informs on the presence or absence of loops but has few features with regards to side chain conformations. Models were built in Coot 69 and refined in PHENIX 70 or Refmac 71 in iterative rounds of manual inspection and building, using simulated annealing and Phenix elbow-derived geometry restraints for the PA warhead where appropriate. Both needle-shaped crystal forms showed pronounced susceptibility to radiation damage, as evident from the merging statistics. Model quality was assessed using the Molprobity analysis tools (3.6-Å USP30 c8~U b-PA structure Ramachandran statistics (favored/allowed/outliers), 94.6/5.1/0.3%; rotamer outliers, 4.9; clashscore, 7.1; 2.3-Å USP30 c13~U b-PA structure Ramachandran statistics (favored/allowed/ outliers), 95.4/4.3/0.3%; rotamer outliers, 3.5; clashscore, 6.7; 2.8-Å USP30 c13i + Lys6-diUb structure, Ramachandran statistics (favored/allowed/outliers), 97.0/3.0/0.0%; rotamer outliers, 2.4; clashscore, 5.0). Final data collection and refinement statistics are summarized in Table 1 .
Fluorescence polarization assays. Measurements were performed with a PheraStar plate reader (BMG Labtech) equipped with an optic module for FlAsH (λ ex = 485 nm, λ em = 520 nm) or TAMRA (λ ex = 540 nm, λ em = 590 nm) fluorophore detection. Data were recorded in black, round-bottom, nonbinding surface 384-well plates (Greiner) at 25 °C in 20 µL (kinetics) or 15 µL (binding experiments). For kinetics, typically one read per min over 60 min was carried out, with 0.1 µM of fluorescent substrate. For binding assays typically 10 reads per well were recorded with 70 nM of fluorescently labeled ubiquitin probe (4 nM ubiquitin-KG-TAMRA was used for the USP21 (C221A) binding experiment). Raw data were referenced against the polarization values as determined by a cuvette-based spectrofluorometer (TAMRA-KG (50 mP), ubiquitin-KG-TAMRA (160 mP) and Lys6-diUb-FlAsH (335 mP)) and were then converted into anisotropies (mA). All experiments were performed in triplicate and in at least two independent experiments. Kinetic experiments were carried out in PBS (pH 7.4) + 5 mM DTT + 0.05 mg/mL BSA. Binding experiments were carried out in 20 mM Tris, pH 8.0, 100 mM NaCl, 5 mM DTT and 0.05 mg/mL BSA. Data were analyzed in the PheraStar Data Analysis program, Microsoft Excel and GraphPad Prism. For kinetic experiments, technical triplicates were averaged, background corrected by subtracting the linear slope of the KG-TAMRA control well or the final part of the curve, and subjected to nonlinear curve fitting to extract the exponential decay in fluorescence (fit: plateau followed by one-phase exponential decay). The observed rate constants obtained thereby were then plotted over the enzyme concentration, yielding catalytic efficiencies as the slopes (identical to the k cat /K M ratio). For binding assays, anisotropies of replicate wells were averaged and plotted in GraphPad Prism for nonlinear curve fitting to determine the affinity constant, K d (fit: one-site binding -total).
Di-and tetraubiquitin cleavage assays. Cleavage of diubiquitin (diUb) and tetraubiquitin (tetraUb) proteins was followed by SDS-PAGE and Coomassie or silver staining. 50-µL reactions were set up by mixing 25 µL 0.5-4.0 µM USP30 (2×) and 25 µL diUb (3-8 µM, 2×) or tetraUb (4 µM, 2×). PBS + 5 mM DTT + 0.05 mg/mL BSA was used as buffer. Reactions were incubated at 37 °C. Aliquots were taken at indicated time points by mixing 10 µL with 5 µL of SDS sample buffer. In the diUb panel comprising all eight linkages, Lys27-diUb was chemically synthesized (UbiQ), whereas all other substrates were enzymatically assembled using wild-type ubiquitin.
For cleavage assays with phosphorylated diubiquitin (Fig. 6h) , samples were diluted in 20 mM Tris, pH 8.0, 100 mM NaCl, 5 mM DTT, 10 mM ATP, 10 mM MgCl 2 and were then treated with PhPINK1 for 720 min. Incorporation of two phosphate groups in Lys11-, Lys48-and Lys63-linked diubiquitin was confirmed by LC-MS.
For gel-based kinetics, assays were carried out as described above and as labeled in the raw data shown in Supplementary Data Set 1. Gels were Coomassie stained (Instant Blue, Expedeon), images of the gels were converted to grayscale, and monoubiquitin band intensities were quantified with ImageJ. Background subtraction was carried out for each band using an identically sized, empty area above the band. Intensities were obtained from multiplying the background-corrected mean signal with the area size. Plotting of the intensity values over time yielded slopes that were used as relative activity measures. Only data in the linear range of the time course were used. Data from the independent experiments were normalized to their respective Lys6-diUb assay and then averaged. Catalytic efficiencies were calculated by quantifying the monoubiquitin bands relative to the diUb bands, taking the different USP30 concentrations into account.
Hydrogen-deuterium exchange mass spectrometry (HDX-MS).
Deuterium exchange reactions of USP30 c2 , USP30 c8 and USP30 c8~U b-PA were initiated by diluting the samples in D 2 O (99.8% D 2 O ACROS) in 20 mM Tris, 50 mM NaCl, 1 mM TCEP (pH 7.5) buffer to give a final D 2 O percentage of 90%. Deuterium labeling was carried out for 3 s on ice in triplicate. The labeling reaction was quenched by the addition of chilled 2.4% (v/v) formic acid in 2 M guanidinium hydrochloride and immediately frozen in liquid nitrogen. Samples were stored at −80 °C before analysis.
The quenched protein samples were rapidly thawed and subjected to proteolytic cleavage by pepsin followed by reversed-phase HPLC separation. Briefly, the protein was passed through an Enzymate BEH immobilized pepsin column, 2.1 × 30 mm, 5 µm (Waters) at 200 µL/min for 2 min, and the peptic peptides were trapped and desalted on a 2.1 × 5 mm C18 trap column (Acquity BEH C18 Vanguard pre-column, 1.7 µm, Waters). Trapped peptides were subsequently eluted over 12 min using a 5-36% gradient of acetonitrile in 0.1% (v/v) formic acid at 40 µL/min. Peptides were separated on a reverse-phase column (Acquity UPLC BEH C18 column 1.7 µm, 100 mm × 1 mm, Waters). Peptides were detected on a SYNAPT G2-Si HDMS mass spectrometer (Waters) acquiring over a m/z of 300 to 2,000, with the standard electrospray ionization (ESI) source and lock mass calibration using [Glu1]-fibrino peptide B (50 fmol/µL). The mass spectrometer was operated at a source temperature of 80 °C and a spray voltage of 2.6 kV. Spectra were collected in positive ion mode.
Peptide identification was performed by MSe 72 using an identical gradient of increasing acetonitrile in 0.1% (v/v) formic acid over 12 min. The resulting MSe data were analyzed using Protein Lynx Global Server software (Waters) with an MS tolerance of 5 ppm.
Mass analysis of the peptide centroids was performed using DynamX software (Waters). Only peptides with a score >6.4 were considered. The first round of analysis and identification was performed automatically by the DynamX software; however, all peptides (deuterated and non-deuterated) were manually verified for the correct charge state, presence of overlapping peptides, and correct retention time. Deuterium incorporation was not corrected for back-exchange and represents relative, rather than absolute changes in deuterium levels. Changes in H/D amide exchange in any peptide may be due to a single amide or a number of amides within that peptide.
Parkin and USP30 ubiquitination assays and mass spectrometry. Ser65phosphorylated HsParkin (pParkin) was generated by phosphorylating HsParkin with GST-tagged PhPINK1, which was then removed by incubation with glutathione-S-Sepharose Beads (Amintra) followed by size-exclusion chromatography (HiLoad 16/600 Superdex 75 pg) and anion-exchange chromatography (Resource Q, GE Healthcare). Spin-filtered pParkin (4 µM) was incubated for 2 h at 37 °C with indicated spin-filtered USP30 constructs (4 µM) in the presence of mouse E1 (0.2 µM), UBE2L3 (2 µM), ubiquitin (120 µM, S65A) and (where indicated) Ser65-phosphorylated ubiquitin (pUb, 12 µM) in reaction buffer (50 mM Tris, pH 8.5, 200 mM NaCl, 10 mM MgCl 2 , 10 mM ATP, 10 mM DTT).
Reactions were quenched using LDS buffer containing β-mercaptoethanol and iodoacetamide. Proteins were resolved on 4-12% NuPAGE gradient Bis-Tris gels (Invitrogen) and transferred to a nitrocellulose or PVDF (only for ubiquitin blot in Supplementary Fig. 10a ) membrane using the Trans-Blot Turbo system (Bio-Rad). Membranes were blocked in a 5% (w/v) milk solution in PBS-T (PBS + 0.1% (v/v) Tween-20) for 30 min and incubated overnight at 4 °C with a primary antibody recognizing either USP30 (HPA016952, Atlas Antibodies), ubiquitin (Ubi-1, NB300-130, Novus Biologicals) or pSer65 ubiquitin (ABS1513-I, Millipore). The membrane was then washed with PBS-T, incubated for 1 h at room temperature with anti-rabbit or anti-mouse IgG-HRP (NA934V or NXA931, GE Healthcare) in 5% (w/v) milk in PBS-T, washed in PBS-T, visualized with Amersham Western Blotting Detection Reagent (GE Healthcare) and imaged using a ChemiDoc Touch Imaging System (Bio-Rad).
For mass spectrometry, assay reactions were separated by SDS-PAGE as described above, and gel bands corresponding to ubiquitinated USP30 were excised. Proteins were then reduced, alkylated and digested with trypsin, using the Janus liquid handling system (PerkinElmer). The digests were subsequently analyzed by LC-MS/MS on a Q-Exactive plus mass spectrometer (ThermoScientific). LC-MS/MS data were searched against an in-house protein database using the Mascot search engine program (Matrix Science) 22 . All data were interrogated manually. USP30 c13~U b F4R was generated to assess the enzymatic activity of monoubiquitinated USP30. pParkin (4 µM) was incubated for 2 h at 37 °C with USP30 c13 (4 µM) in the presence of human E1 (0.2 µM), UBE2L3 (2 µM), ubiquitin F4R (30 µM) and staurosporine (10 µM) in reaction buffer (20 mM Tris, pH 8.5, 200 mM NaCl, 10 mM MgCl 2 , 1 mM ATP, 0.7 mM DTT). Monoubiquitinated and free USP30 were partially separated through anion-exchange chromatography (Resource Q, 1 ml, GE Healthcare, buffers as during purification), and protein concentrations were determined through densitometry of Coomassie-stained gels of concentrated fractions that were subsequently assayed for ubiquitin-KG-TAMRA cleavage activity as described above.
USP30(C77A) c13~U b was generated to assess the effect of phosphoubiquitin on USP30 auto-deubiquitination. pParkin (4 µM) was incubated for 2 h at 37 °C with USP30(C77A) c13i (4 µM) in the presence of human E1 (0.2 µM), UBE2L3 (2 µM), ubiquitin (30 µM) in reaction buffer (20 mM Tris, pH 8.5, 200 mM NaCl, 10 mM MgCl 2 , 1 mM ATP, 0.7 mM DTT). The reaction was then incubated with either GST-PhPINK1 (2 µM) or with λ-phosphatase (6 µM), 1 mM MnCl 2 and staurosporine (10 µM) followed by incubation with Apyrase (NEB) and 5 mM CaCl 2 . Samples were then buffer exchanged into storage buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 5% (v/v) glycerol), 5 mM DTT), concentrated and incubated with USP30 c13 (0.25 µM) in PBS + 5 mM DTT for indicated times. Disappearance of the USP30(C77A) c13~p Ub species was followed by western blotting for USP30 as described above. Corresponding author(s): David Komander
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